US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi

The U.S. won’t step in to slash the price of Pfizer and Astellas’ pricey prostate cancer med Xtandi, drawing the ire of patent experts and lawmakers alike.

Tuesday, the National Institutes of Health (NIH) rejected a petition to exercise so-called "march-in" authority around the drug. The same fate befell a similar petition back in 2016.